Information checked: November 16, 2026, 1:08 p.m. London time (GMT, UTC+00:00; 13:08 UTC).
People in England with persistent acid reflux and additional risk factors for esophageal disease could gain wider access to a quick, less-invasive “sponge on a string” test under new draft guidance published by the National Institute for Health and Care Excellence (NICE). The proposals cover two capsule-sponge technologies, Cytosponge and EndoSign, and would allow eligible patients to be assessed closer to home rather than relying only on hospital endoscopy pathways.
The announcement is a significant step toward broader NHS use, but it is not confirmation that the test has already been rolled out nationwide. NICE’s recommendations remain a draft, and the proposed pathway is aimed at selected higher-risk patients—not everyone who experiences indigestion. The technology is intended to help identify Barrett’s esophagus and concerning cell changes, not to provide a stand-alone cancer diagnosis.
Destaques
- Two tests are covered: NICE’s draft supports Cytosponge and EndoSign for selected people with persistent acid reflux and additional risk factors.
- The test is less invasive: a patient swallows a small capsule attached to a thread; a sponge collects cells from the esophagus when it is gently withdrawn.
- It is not a universal cancer screen: people still need clinical assessment, and suspicious findings may require a gastroscopy to confirm a diagnosis.
- The decision is not final: NICE lists the related technology appraisal for publication on February 24, 2027, so access arrangements could still change.
What has NICE recommended for the NHS cancer sponge test?
NICE’s draft guidance recommends offering capsule-sponge tests to people with persistent gastroesophageal reflux disease (GORD in UK terminology) who also have risk factors associated with Barrett’s esophagus or esophageal cancer, where an urgent suspected-cancer referral is not required. The proposals also consider the tests as another way to monitor some people who have already been diagnosed with Barrett’s esophagus.
That distinction matters. Long-lasting heartburn or indigestion alone does not automatically make someone eligible. A clinician must consider the person’s symptoms, medical history, risk factors, and whether a different or more urgent investigation is needed. The draft does not replace clinical judgment or the existing urgent cancer-referral pathway.
The recommendations are the first to come from NICE’s National HealthTech Access Programme, which assesses selected medical devices, diagnostic tests, and digital technologies for possible routine NHS use. NICE says that, if a technology is recommended in final guidance, eligible patients in England should be able to access it consistently when it is considered the most suitable option. The official NICE guidance-in-development listing identifies the capsule-sponge appraisal and gives February 24, 2027, as its expected publication date.
Why is the NHS considering a sponge test for persistent indigestion?
The clinical focus is Barrett’s esophagus, a condition in which cells in the lining of the lower esophagus change, often after long-term exposure to stomach acid. Barrett’s can increase the risk of esophageal cancer, although most people with the condition will not develop cancer. NICE’s announcement says the condition affects an estimated 1% to 2% of adults and is more common among people with long-term reflux.
Finding Barrett’s and identifying patients who need closer investigation may help the NHS direct endoscopy appointments toward people most likely to benefit. Demand for endoscopy is high, and NICE has noted that some patients with Barrett’s are not being monitored as often as recommended. The intended benefit is therefore twofold: provide an easier first assessment for suitable patients and preserve specialist endoscopy capacity for people who need a closer examination or treatment.
Evidence reviewed by Cancer Research UK reports that capsule-sponge triage evaluations in England and Scotland reduced demand for endoscopy in the studied pathways. Those results are encouraging for service planning, but they do not prove that a national rollout will automatically shorten every patient’s waiting time or reduce cancer deaths. Long-term outcomes and access across different communities still need evaluation.
How does the Cytosponge or EndoSign test work?
The test is sometimes called a “pill on a thread” or “sponge on a string.” A patient swallows a small capsule with water. The capsule dissolves in the stomach and releases a compressed sponge attached to a thin thread. After a few minutes, a trained health professional gently pulls the thread to bring the sponge back through the esophagus. As it passes, the sponge collects cells from the esophageal lining.
The sample is sent to a laboratory for analysis for changes associated with Barrett’s esophagus and, in some cases, early esophageal cancer. The procedure does not require sedation and can be carried out in primary-care facilities or community diagnostic settings. Cancer Research UK describes the test as quicker and less invasive than a gastroscopy, while noting that the exact pathway depends on the clinical purpose and local service arrangements.
A result that suggests an abnormality is not, by itself, a confirmed cancer diagnosis. A gastroscopy—also called an upper endoscopy—may be needed to examine the esophagus directly, take a biopsy, and establish the diagnosis and severity. The Cancer Research UK clinical overview of capsule-sponge testing explains the procedure, its uses, and its limitations.
Does the sponge test replace endoscopy or screen everyone for cancer?
No. The proposal is a targeted diagnostic pathway, not a population-wide screening program for everyone with heartburn. It is also not a blanket replacement for endoscopy. Gastroscopy remains important when clinicians need a direct view of the esophagus, tissue samples, or confirmation of a suspicious result. People with established Barrett’s may still need monitoring according to their individual risk and the final clinical pathway.
The sponge test also has limitations. It may not collect an adequate sample every time, and some patients may need a repeat test. It does not detect every case of Barrett’s esophagus, and it is designed to assess the esophagus rather than investigate every possible cause of indigestion or stomach symptoms. A negative result should not be treated as a guarantee that cancer or another condition is absent, particularly if symptoms persist, change, or worsen.
For that reason, the NICE proposal emphasizes an appropriate place for the test within the wider pathway, including clear follow-up arrangements. Clinicians must still decide when symptoms call for endoscopy or another investigation rather than a capsule sponge.
Where is the NHS sponge test available, and when could access expand?
Capsule-sponge testing is already used in some NHS hospitals and community diagnostic services. In July 2025, NHS England announced a two-year pharmacy pilot with Boots, Cyted Health, and cancer alliances in London and the East Midlands. The plan was to offer testing to around 1,500 people through participating pharmacies or referrals to community clinics, with an independent evaluation informing decisions about any wider rollout. The NHS England pilot announcement describes that earlier stage of implementation.
The November 16 NICE draft is a broader policy development: it proposes a consistent route for eligible patients across England if the recommendations are confirmed. It should not be interpreted as proof that every GP practice or pharmacy can provide the test immediately. Local availability, trained staff, laboratory capacity, referral arrangements, and the final wording of the guidance will all affect how quickly services can adopt it.
The current NICE timetable lists February 24, 2027, as the expected publication date for the related technology appraisal. Until final guidance is issued, the draft may be revised. The proposal applies to the NHS in England; health services in Scotland, Wales, and Northern Ireland have their own arrangements and should not be assumed to follow the same timetable.
What should people with persistent heartburn or indigestion do now?
People should not wait for a sponge test to become available if they are worried about ongoing symptoms. The NHS advises contacting a GP if heartburn occurs most days for three weeks or more, if swallowing becomes difficult, if there is noticeable unexplained weight loss, or if digestive symptoms worsen or stop responding to usual treatment. These symptoms can have many causes and do not automatically mean cancer, but they deserve medical assessment.
Difficulty swallowing, worsening symptoms, or unexplained weight loss should be discussed with a health professional rather than self-treated indefinitely. If someone is unsure where to seek help for concerning symptoms, NHS 111 can provide advice; severe or immediately life-threatening symptoms require emergency help. The NHS guide to esophageal cancer symptoms sets out when to contact a GP or seek urgent advice.
For now, the practical message is straightforward: persistent reflux is worth discussing with a clinician, but the capsule sponge is a targeted option—not a substitute for an assessment. NICE’s draft could make that option more consistent across England if it becomes final in 2027.
FAQ: NHS cancer sponge test
Is the sponge test a test for esophageal cancer?
It collects esophageal cells to look for Barrett’s esophagus and concerning changes. An abnormal result may lead to a gastroscopy and biopsy; the sponge test alone does not confirm cancer.
Can anyone with indigestion ask for Cytosponge or EndoSign?
No. NICE’s draft is aimed at selected people with persistent reflux and additional risk factors, subject to clinical assessment. It is not a routine test for every person with indigestion.
When will the NHS rollout begin?
There is no confirmed nationwide start date yet. The recommendations are still in draft form, and NICE currently lists February 24, 2027, as the expected publication date for the related appraisal.